research Baricitinib: From Rheumatoid Arthritis to COVID-19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
Search
for
Sort by
Research
120-150 / 423 results 
research Particulate Matter Induces Inflammatory Response in Human Outer Root Sheath Cells via Oxidative Stress-Dependent MAPK and JAK-STAT Signaling Pathways
Particulate matter causes inflammation in hair cells, potentially harming hair growth.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
research Generating Detailed Intercellular Communication Patterns in Psoriasis at the Single-Cell Level Using Social Networking, Pattern Recognition, and Manifold Learning Methods to Optimize Treatment Strategies
New insights into cell communication in psoriasis suggest innovative drug treatments.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Cutaneous Transcriptome Analysis in NIH Hairless Mice
Key genes linked to hair growth and cancer were identified in hairless mice.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research XMU-MP-1 Induces Growth Arrest in a Model Human Mini-Organ and Antagonizes Cell Cycle-Dependent Paclitaxel Cytotoxicity
XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
research An Urticarial Drug Eruption Caused by Tofacitinib for Alopecia Universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Characterization of Novel TMEM173 Mutation with Additive IFIH1 Risk Allele
A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata
Regenerative therapies show promise for treating vitiligo and alopecia areata.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Myocardial NF-κB Activation Is Essential for Zebrafish Heart Regeneration
NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Alopecia Areata Triggered by Psychological Stress and Successfully Treated with a Janus Kinase Inhibitor: Case Report
Stress-related hair loss was reversed with a special medication.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib
Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
research Shedding Light on Therapeutics in Alopecia and Their Relevance to COVID-19
Some alopecia treatments might help treat COVID-19, but more research is needed.